Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To investigate the efficacy and safety of various medical treatment schemes in the management of patients at high risk of progression of benign prostatic hyperplasia (BPH), depending on concomitant erectile dysfunction (ED). Materials and methods. The study comprised 247 men with an I-PSS score of 8 or more, a prostate volume of more than 40 cm3, and a prostate specific antigen level of 1.5-4.0 ng/ml. Patients were divided into 2 groups: group 1 included patients without ED (IIEF-5 score >21); patients of group 2 had ED (IIEF-5 score ≤21). Within the groups, two subgroups of patients with a maximum flow rate (Qmax) >10 ml/s were identified (subgroup A), and with Qmax≤10 ml/s (subgroup B). Patients of subgroup A of group 1 received a 5α-reductase inhibitor, subgroup B of group 1received an a1-adrenoblocker, and 5α-reductase inhibitor, subgroup A of group 2 were treated with a 5α-reductase inhibitor and a phosphodiesterase type 5 inhibitor (PDE-5), subgroup B of group 2 received an a1-adrenoblocker, 5α-reductase inhibitor, and PDE-5 inhibitor. The results were evaluated at 3, 6, and 12 months. Results. All schemes of combination therapy showed a significant improvement in I-PSS, QoL, Qmax and residual urine volume after three months of treatment, while in patients receiving monotherapy with 5α-reductase inhibitor improvement occurred at six months after treatment initiation. There were no significant differences in the incidence of side effects between these treatment options. The use of the PDE-5 inhibitor can successfully compensate the negative effect of the 5α-reductase inhibitor on male sexual function. Conclusion. The most effective treatment option for BPH patients without ED is a combination of a1-adrenoblocker and 5α-reductase inhibitor. In BPH patients with ED, a two- and a three-component combination including a PDE-5 inhibitor provides a significant improvement in both erectile function and lower urinary tract symptoms secondary to BPH. Multicomponent therapy schemes are not accompanied by a significant increase in the incidence of adverse reactions.

Full Text

Restricted Access

About the authors

A. A Kamalov

Lomonosov MSU

Academician of the RAS, Dr.Med.Sci., Prof., Head of the Department of Urology and Andrology, Faculty of Fundamental Medicine, Lomonosov MSU, Director of the MSU University Clinic

A. M Takhirzade

Lomonosov MSU

Email: anar391@rambler.ru
Ph.D. Student at the Department of Urology and Andrology, Faculty of Fundamental Medicine

References

  1. Gacci M., Eardley I., Giuliano F., Hatzichristou D., Kaplan S.A., Maggi M., McVary K.T., Mirone V., Porst H., Roehrborn C.G. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011 ;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037.
  2. Kardasevic A., Milicevic S. The Correlation Between Prostate Volume in Patients with Benign Prostatic Hyperplasia in Relation to Erectile Dysfunction. Med Arch. 2016;70(6):449-52. Doi: 10.5455/ medarh.2016.70.449-452.
  3. Blanker M.H., Bohnen A.M., Groeneveld F.P., Bernsen R.M., Prins A., Thomas S., Bosch J.L. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J. Am Geriatr Soc. 2001;49(4):436-442.
  4. Rosen R. ,Altwein J., Boyle P., Kirby R.S.,Lukacs B., Meuleman E., O’Leary M.P., Puppo P., Robertson C., Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637-649.
  5. Shimizu S., Tsounapi P., Shimizu T., Honda M., Inoue K., Dimitriadis F., Saito M. Lower urinary tract symptoms, benign prostatic hyperplasia/ benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction? Int J. Urol. 2014;21(9):856-864.
  6. Glina S., Glina F.P. Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction. Ther Adv Urol. 2013;5(4):211-218.
  7. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). 2017 [Electronic resource]. S. Gravas, T. Bach, M. Drake [et al.]. - Режим доступа: http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts.
  8. Камалов А.А., Охоботов Д.А., Тахирзаде А.М., Осмоловский Б.Е., Тахирзаде Т.Б., Геворкян А.Р. Комбинированная терапия больных с симптомами нижних мочевых путей и эректильной дисфункцией. Естественные и технические науки. 2013;1:105-113
  9. Камалов А.А., Осмоловский Б.Е., Охоботов Д.А., Ходырева Л.А., Тахирзаде Т.Б., Тахирзаде А.М., Геворкян А.Р. Комбинированное лечение больных эректильной дисфункцией, страдающих расстройствами мочеиспускания. Урология. 2013; 3:29-33
  10. Мартазинова С.К., Щеплев П.А. Эффективность и безопасность комбинированного применения альфа1-адреноблокатора доксазозина и ингибитора фосфодиэстеразы 5-го типа уденафила у больных доброкачественной гиперплазией предстательной железы. Андрология и генитальная хирургия. 2013;2:69-73
  11. Roehrborn C.G., Egan K.B., Miner M.M., Ni X., Wong D.G., Rosen R.C. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment. BJU Int. 2016;118(1):153-160.
  12. Lee L.K., Goren A., Boytsov N.N., Donatucci C.F., McVary K.T. Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations. Patient Prefer Adherence. 2016;10:1205-1215.
  13. Wang X.H., Wang X., Shi M.J., Li S., Liu T., Zhang X.H. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and а-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. Asian J. Androl. 2015;17(6):1022-1032.
  14. Casabé A., Roehrborn C.G., Da Pozzo L.F., Zepeda S., Henderson R.J., Sorsaburu S., Henneges C., Wong D.G., Viktrup L. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J. Urol. 2014;191(3):727-733.
  15. Park H.J., Park N.C. Combination therapy with dutasteride and tadalafil in men with moderate-to-severe benign prostatic hyperplasia. Eur Urol Suppl. 2013;12;e1092.
  16. Волков А.А., Петричко М.И., Будник Н.В. Ежедневный прием ингибиторов фосфодиэстеразы 5-го типа - коррекция эректильной дисфункции и симптомов нижних мочевых путей у больных аденомой предстательной железы. Урология. 2014;4:64-68
  17. Wang K., Jin S., Fan D., Wang M., Xing N., Niu Y. Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene. PLoS One. 2017;12(2):e0172233. Doi: 10.1371/ journal.pone.0172233.
  18. Волков А.А., Петричко М.И., Будник Н.В., Духин А.Р. Тадалафил у больных аденомой предстательной железы при проведении консервативной комбинированной терапии. Урология. 2013;2:56-59
  19. Волков А.А., Петричко М.И., Будник Н.В. Коррекция эректильной дисфункции у больных аденомой предстательной железы ежедневным приемом тадалафила 5 мг на фоне комбинированной лекарственной терапии. Урология. 2013;5:50-54

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies